Mayo Clinic LogoSide effects of cancer seem devastating for patients, therefore a therapy that could help avoid the latter would more than welcome . Mayo Clinic investigators and collaborators from the United Kingdom reveal to have treated well-developed prostate tumors in mice by administering human vaccine to them with no side effects.

This research apparently paves way to treatment of prostate cancer and melanoma. It can also play an essential role in treating other malignant cancers affecting the lungs, brains and pancreatic portions. The research brought to fore that there was apparently no sign of autoimmune diseases in the mice. The other tissue remained unaffected as the murine T-cells targeted only cancerous prostate cells.

Richard Vile, Ph.D., Mayo Clinic immunologist, Richard M. Schulze Family Foundation Professor and a lead author of the finding, remarked “We are hopeful that this will overcome some of the major hurdles which we have seen with immunotherapy cancer research.”

Clinical trials could begin within two years. Geneticists gathered scraps of genetic encryptions from healthy human prostate tissue into a complementary DNA also known as the cDNA library. These pieces of were then made to enter a crowd of vesicular stomatitis viruses (VSV), which were nurtured and made to re-enter the test mice in the form of a vaccine in the due course of intravenous injections.

The growth of extensive cDNA libraries from healthy human prostate tissue seems to jailbreak the key to effective immunotherapy. A molecular protein tag known as antigen that seems to evoke an increased response from the body’s immune system is believed to be present in all sorts of infections, tissue and allergens. With an aim of a massive attack from the mice’s T-cells, the human cancer prostate antigens were employed though the mutated VSV vector. After they were exposed to the mutated viruses, the animals’ immune systems became familiar with the antigens expressed in the virus and resulted in extensive and capable immune response to attack the prostate tumors.

Researchers believe that no one has an idea as to how many antigens the immune system is capable of finding on tumor cells. The expression of all of these proteins in highly immunogenic viruses apparently increased the visibility to the immune system. The system then gets to know that its territory is being invaded by virus that express cancer related antigens and seeks to eliminate those.

Earlier efforts to vaccinate prostate and other types of cancers have been largely perturbed as the scientists couldn’t identify an adequately varied and robust group of antigens in tumor cells. It is this reason that tends to result in tumors often mutating and then re-developing them though the body’s immune system is at work.

The difficult in isolating antigens in tumor cells could be overcome by the use of viruses as vectors of cDNA. This is done by giving the immune system a clearer picture of the invading tumor.

The research is published in the journal Nature Medicine.